Provided by Tiger Trade Technology Pte. Ltd.

Alterity Therapeutics Limited

3.07
-0.2500-7.53%
Post-market: 3.100.0300+0.98%16:10 EDT
Volume:34.37K
Turnover:107.87K
Market Cap:58.62M
PE:-3.33
High:3.34
Open:3.21
Low:3.04
Close:3.32
52wk High:5.89
52wk Low:2.66
Shares:19.10M
Float Shares:14.24M
Volume Ratio:1.03
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9231
EPS(LYR):-0.9231
ROE:-54.98%
ROA:-34.08%
PB:1.97
PE(LYR):-3.33

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Oct 05

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

GlobeNewswire
·
Oct 05

Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy

TIPRANKS
·
Aug 11

Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference

GlobeNewswire
·
Aug 06

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Jul 30

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

GlobeNewswire
·
Jul 21

Alterity Therapeutics initiated with a Buy at JonesResearch

TIPRANKS
·
Jun 30

Alterity Therapeutics assumed with a Buy at Ladenburg

TIPRANKS
·
Jun 16

Top Premarket Decliners

MT Newswires Live
·
Jun 11

Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA

TIPRANKS
·
Jun 09

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

GlobeNewswire
·
Jun 09

Alterity Therapeutics publishes quantitative susceptibility mapping MRI data

TIPRANKS
·
May 11

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

GlobeNewswire
·
May 07

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Apr 30

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

GlobeNewswire
·
Apr 22

Alterity Therapeutics appoints Ann Cunningham to board as independent director

Reuters
·
Apr 17

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

GlobeNewswire
·
Apr 15